IFNG and ovarian cancer: The intraperitoneal administration of recombinant human IFN-γ yielded a 23% complete regression (CR) rate in ovarian cancer patients with residual diseases.95 In the first-line therapy for ovarian cancer, the combination of chemotherapy with subcutaneous IFN-γ treatment demonstrated a superior therapeutic efficacy compared to chemotherapy alone.